Human Vav1 expression in hematopoietic and cancer cell lines is regulated by c-Myb and by CpG methylation

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Ilan, Lena ^a   Katzav, Shulamit ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BISULFITE; LUCIFERASE; PROTEIN C MYB; PROTEIN VAV1; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG; VAV PROTEIN; MYC PROTEIN; TRANSCRIPTION FACTOR; VAV1 PROTEIN, HUMAN;

ARTICLE; BINDING SITE; CANCER CELL CULTURE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; GENE CONSTRUCT; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE IDENTIFICATION; GENE SEQUENCE; GENETIC TRANSFECTION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE; MARKER GENE; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PROMOTER REGION; PROTEIN BINDING; REPORTER GENE; TRANSCRIPTION INITIATION; TRANSCRIPTION INITIATION SITE; VAV1 GENE; 5' UNTRANSLATED REGION; ANTIBODY SPECIFICITY; GENETICS; HEMATOPOIETIC SYSTEM; LUNG TUMOR; METABOLISM; MOLECULAR GENETICS; MUTATION; PATHOLOGY; TUMOR CELL LINE;

5' UNTRANSLATED REGIONS; BASE SEQUENCE; BINDING SITES; CELL LINE, TUMOR; CPG ISLANDS; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HEMATOPOIETIC SYSTEM; HUMANS; LUNG NEOPLASMS; MOLECULAR SEQUENCE DATA; MUTATION; ORGAN SPECIFICITY; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-MYC; PROTO-ONCOGENE PROTEINS C-VAV; TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 84855676050     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029939     Document Type: Article

References (52)

1. Meister P, Mango SE, Gasser SM, (2011) Locking the genome: nuclear organization and cell fate. Curr Opin Genet Dev 21: 167-174.
2. Wilson NK, Calero-Nieto FJ, Ferreira R, Gottgens B, (2011) Transcriptional regulation of haematopoietic transcription factors. Stem Cell Res Ther 2: 6.
3. Katzav S, Martin-Zanca D, Barbacid M, (1989) vav, a novel human oncogene derived from a locus ubiquitously expressed in hematopoietic cells. EMBO J 8: 2283-2290.
4. Okada H, Watanabe T, Niki M, Takano H, Chiba N, et al. (1998) AML1(-/-) embryos do not express certain hematopoiesis-related gene transcripts including those of the PU.1 gene. Oncogene 17: 2287-2293.
5. Jaffredo T, Gautier R, Eichmann A, Dieterlen-Lievre F, (1998) Intraaortic hemopoietic cells are derived from endothelial cells during ontogeny. Development 125: 4575-4583.
6. Tybulewicz VL, (2005) Vav-family proteins in T-cell signalling. Curr Opin Immunol 17: 267-274.
7. Bustelo XR, (2000) Regulatory and signaling properties of the Vav family. Mol Cell Biol 20: 1461-1477.
8. Crespo P, Schuebel KE, Ostrom AA, Gutkind JS, Bustelo XR, (1997) Phosphotyrosine-dependent activation of Rac-1 GDP/GTP exchange by the vav proto-oncogene product. Nature 385: 169-172.
9. Katzav S, Cleveland JL, Heslop HE, Pulido D, (1991) Loss of the amino-terminal helix-loop-helix domain of the vav proto-oncogene activates its transforming potential. Mol Cell Biol 11: 1912-1920.
10. Ogilvy S, Elefanty AG, Visvader J, Bath ML, Harris AW, et al. (1998) Transcriptional regulation of vav, a gene expressed throughout the hematopoietic compartment. Blood 91: 419-430.
11. Ogilvy S, Metcalf D, Gibson L, Bath ML, Harris AW, et al. (1999) Promoter elements of vav drive transgene expression in vivo throughout the hematopoietic compartment. Blood 94: 1855-1863.
12. Almarza E, Segovia JC, Guenechea G, Gomez SG, Ramirez A, et al. (2004) Regulatory elements of the vav gene drive transgene expression in hematopoietic stem cells from adult mice. Exp Hematol 32: 360-364.
13. Almarza E, Zhang F, Santilli G, Blundell MP, Howe SJ, et al. (2011) Correction of SCID-X1 using an enhancerless Vav promoter. Hum Gene Ther 22: 263-270.
14. Turner SD, Tooze R, Maclennan K, Alexander DR, (2003) Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase. Oncogene 22: 7750-7761.
15. Denkinger DJ, Lambrecht TQ, Cushman-Vokoun AM, Kawahara RS, (2002) PU.1 regulates the expression of the vav proto-oncogene. J Cell Biochem 84: 772-783.
16. Brugnoli F, Lambertini E, Varin-Blank N, Piva R, Marchisio M, et al. (2010) Vav1 and PU.1 are recruited to the CD11b promoter in APL-derived promyelocytes: role of Vav1 in modulating PU.1-containing complexes during ATRA-induced differentiation. Exp Cell Res 316: 38-47.
17. Coppola J, Bryant S, Koda T, Conway D, Barbacid M, (1991) Mechanism of activation of the vav protooncogene. Cell Growth Differ 2: 95-105.
18. Bustelo XR, Suen KL, Leftheris K, Meyers CA, Barbacid M, (1994) Vav cooperates with Ras to transform rodent fibroblasts but is not a Ras GDP/GTP exchange factor. Oncogene 9: 2405-2413.
19. Katzav S, Packham G, Sutherland M, Aroca P, Santos E, et al. (1995) Vav and Ras induce fibroblast transformation by overlapping signaling pathways which require c-Myc function. Oncogene 11: 1079-1088.
20. Katzav S, (2007) Flesh and blood: the story of Vav1, a gene that signals in hematopoietic cells but can be transforming in human malignancies. Cancer Lett 255: 241-254.
21. Hornstein I, Pikarsky E, Groysman M, Amir G, Peylan-Ramu N, et al. (2003) The haematopoietic specific signal transducer Vav1 is expressed in a subset of human neuroblastomas. J Pathol 199: 526-533.
22. Fernandez-Zapico ME, Gonzalez-Paz NC, Weiss E, Savoy DN, Molina JR, et al. (2005) Ectopic expression of VAV1 reveals an unexpected role in pancreatic cancer tumorigenesis. Cancer Cell 7: 39-49.
23. Lazer G, Pe'er L, Farago M, Machida K, Mayer BJ, et al. (2010) Tyrosine residues at the carboxyl terminus of Vav1 play an important role in regulation of its biological activity. J Biol Chem 285: 23075-23085.
24. Weiss A, Wiskocil RL, Stobo JD, (1984) The role of T3 surface molecules in the activation of human T cells: a two-stimulus requirement for IL 2 production reflects events occurring at a pre-translational level. J Immunol 133: 123-128.
25. Larrick JW, Fischer DG, Anderson SJ, Koren HS, (1980) Characterization of a human macrophage-like cell line stimulated in vitro: a model of macrophage functions. J Immunol 125: 6-12.
26. Brower M, Carney DN, Oie HK, Gazdar AF, Minna JD, (1986) Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium. Cancer Res 46: 798-806.
27. Klemsz MJ, McKercher SR, Celada A, Van Beveren C, Maki RA, (1990) The macrophage and B cell-specific transcription factor PU.1 is related to the ets oncogene. Cell 61: 113-124.
28. Mouthon MA, Bernard O, Mitjavila MT, Romeo PH, Vainchenker W, et al. (1993) Expression of tal-1 and GATA-binding proteins during human hematopoiesis. Blood 81: 647-655.
29. Anantharaman A, Lin IJ, Barrow J, Liang SY, Masannat J, et al. (2011) Role of helix-loop-helix proteins during differentiation of erythroid cells. Mol Cell Biol 31: 1332-1343.
30. Greig KT, de Graaf CA, Murphy JM, Carpinelli MR, Pang SH, et al. (2010) Critical roles for c-Myb in lymphoid priming and early B-cell development. Blood 115: 2796-2805.
31. Sandberg ML, Sutton SE, Pletcher MT, Wiltshire T, Tarantino LM, et al. (2005) c-Myb and p300 regulate hematopoietic stem cell proliferation and differentiation. Dev Cell 8: 153-166.
32. Katryniok C, Schnur N, Gillis A, von Knethen A, Sorg BL, et al. (2010) Role of DNA methylation and methyl-DNA binding proteins in the repression of 5-lipoxygenase promoter activity. Biochim Biophys Acta 1801: 49-57.
33. Bustelo XR, Rubin SD, Suen KL, Carrasco D, Barbacid M, (1993) Developmental expression of the vav protooncogene. Cell Growth Differ 4: 297-308.
34. Feng D, Kan YW, (2005) The binding of the ubiquitous transcription factor Sp1 at the locus control region represses the expression of beta-like globin genes. Proc Natl Acad Sci U S A 102: 9896-9900.
35. Persson M, Andren Y, Mark J, Horlings HM, Persson F, et al. (2009) Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci U S A 106: 18740-18744.
36. Schapira V, Lazer G, Katzav S, (2006) Osteopontin is an oncogenic Vav1- but not wild-type Vav1-responsive gene: implications for fibroblast transformation. Cancer Res 66: 6183-6191.
37. Gupta P, Gurudutta GU, Saluja D, Tripathi RP, (2009) PU.1 and partners: regulation of haematopoietic stem cell fate in normal and malignant haematopoiesis. J Cell Mol Med 13: 4349-4363.
38. Wei GH, Badis G, Berger MF, Kivioja T, Palin K, et al. (2010) Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo. EMBO J 29: 2147-2160.
39. Sokalski KM, Li SK, Welch I, Cadieux-Pitre HA, Gruca MR, et al. (2011) Deletion of genes encoding PU.1 and Spi-B in B cells impairs differentiation and induces pre-B cell acute lymphoblastic leukemia. Blood.
40. Mucenski ML, McLain K, Kier AB, Swerdlow SH, Schreiner CM, et al. (1991) A functional c-myb gene is required for normal murine fetal hepatic hematopoiesis. Cell 65: 677-689.
41. Kopecki Z, Luchetti MM, Adams DH, Strudwick X, Mantamadiotis T, et al. (2007) Collagen loss and impaired wound healing is associated with c-Myb deficiency. J Pathol 211: 351-361.
42. Malaterre J, Carpinelli M, Ernst M, Alexander W, Cooke M, et al. (2007) c-Myb is required for progenitor cell homeostasis in colonic crypts. Proc Natl Acad Sci U S A 104: 3829-3834.
43. Malaterre J, Mantamadiotis T, Dworkin S, Lightowler S, Yang Q, et al. (2008) c-Myb is required for neural progenitor cell proliferation and maintenance of the neural stem cell niche in adult brain. Stem Cells 26: 173-181.
44. Biroccio A, Benassi B, D'Agnano I, D'Angelo C, Buglioni S, et al. (2001) c-Myb and Bcl-x overexpression predicts poor prognosis in colorectal cancer: clinical and experimental findings. Am J Pathol 158: 1289-1299.
45. Ramsay RG, Gonda TJ, (2008) MYB function in normal and cancer cells. Nat Rev Cancer 8: 523-534.
46. Chen RX, Xia YH, Xue TC, Ye SL, (2010) Transcription factor c-Myb promotes the invasion of hepatocellular carcinoma cells via increasing osteopontin expression. J Exp Clin Cancer Res 29: 172.
47. Lazer G, Idelchuk Y, Schapira V, Pikarsky E, Katzav S, (2009) The haematopoietic specific signal transducer Vav1 is aberrantly expressed in lung cancer and plays a role in tumourigenesis. J Pathol 219: 25-34.
48. Landolin JM, Johnson DS, Trinklein ND, Aldred SF, Medina C, et al. (2010) Sequence features that drive human promoter function and tissue specificity. Genome Res 20: 890-898.
49. Nagae G, Isagawa T, Shiraki N, Fujita T, Yamamoto S, et al. (2011) Tissue-specific demethylation in CpG-poor promoters during cellular differentiation. Hum Mol Genet 20: 2710-2721.
50. Denkinger DJ, Kawahara RS, (1997) Expression of the vav oncogene in somatic cell hybrids. Exp Cell Res 232: 388-394.
51. Sincic N, Herceg Z, (2011) DNA methylation and cancer: ghosts and angels above the genes. Curr Opin Oncol 23: 69-76.
52. Iguchi-Ariga SM, Schaffner W, (1989) CpG methylation of the cAMP-responsive enhancer/promoter sequence TGACGTCA abolishes specific factor binding as well as transcriptional activation. Genes Dev 3: 612-619.